Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394251 · ClinicalTrials.gov registry record · Phase 2
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00394251 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 197 participants.
The verdict
NCT00394251, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Interventions
- DRUG Bevacizumab
- DRUG pegfilgrastim
- DRUG Taxol
- DRUG ABI-007
- DRUG Adriamycin and Cytoxan (AC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2006-08-01 |
| Est. Completion | 2008-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394251
The ClinicalTrials.gov registry entry for NCT00394251 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00394251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394251 about?
NCT00394251 is a clinical study titled "Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer". The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then...
What is the current status of trial NCT00394251?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2006-08-01. Estimated completion is 2008-02-01.
What interventions are being tested in trial NCT00394251?
The interventions under investigation include: Bevacizumab (DRUG), pegfilgrastim (DRUG), Taxol (DRUG), ABI-007 (DRUG), Adriamycin and Cytoxan (AC) (DRUG).
Who is sponsoring clinical trial NCT00394251?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.